A randomized, open-label, multicenter, 4-week study to evaluate the tolerability and pharmacokinetics of ITCA 650 in patients with type 2 diabetes

Clinical Therapeutics

Volumn 35, Issue 5, 2013, Pages

  Henry, Robert R ^a,b   Logan, Douglas ^c   Alessi, Thomas ^d   Baron, Michelle A ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c Medpace Clinical Pharmacology Unit ^*  (United States)

^d Research Triangle   (United States)

Author keywords

Exenatide; ITCA 650; Pharmacodynamics; Pharmacokinetics; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; EXENDIN 4; HEMOGLOBIN A1C; INSULIN; ITCA 650; METFORMIN; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; DECREASED APPETITE; DIET; DRUG TOLERABILITY; EXERCISE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; ORTHOSTATIC HYPOTENSION; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; VOMITING;

EID: 84877927928     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2013.03.011     Document Type: Article

References (23)

1. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011 2011, Centers for Disease Control and Prevention, US Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, Ga.
2. Inzucchi S.E., Bergenstal R.M., Buse J.B., et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012, 35:1364-1379. American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD).
3. Cheung B.M., Ong K.L., Cherny S.S., et al. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med 2009, 122:443-453.
4. Esposito K., Mosca C., Brancario C., et al. GLP-1 receptor agonists and HBA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Curr Med Res Opin 2011, 27:1519-1528.
5. Henry R.R., Buse J.B., Sesti G., et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta-analysis of the liraglutide development program. Endocr Pract 2011, 17:906-913.
6. Resnick H.E., Foster G.L., Bardsley J., Ratner R.E. Achievement of American Diabetes Association clinical practice recommendations among US adults with diabetes, 1999-2002. Diabetes Care 2006, 29:531-537.
7. Meier J.J. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012, 8:728-742.
8. Tzefos M., Harris K., Brackett A. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults. Ann Pharmacother 2012, 46:68-78.
9. Kolterman O.G., Buse J.B., Fineman M.S., et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003, 88:3082-3089.
10. Kolterman O.G., Kim D.D., Shen L., et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005, 62:173-181.
11. Kim D., MacConell L., Zhuang D., et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007, 30:1487-1493.
12. Drucker D.J., Buse J.B., Taylor K., et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomized, open-label, non-inferiority study. Lancet 2008, 372:1240-1250.
13. Gallwitz B., Guzman J., Dotta F., et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial. Lancet 2012, 379:2270-2278.
14. MacConnell L., Li Y., Pencek R., et al. Exenatide once weekly resulted in sustained improvement in glycemic control with weight loss through 4 years. Diabetes 2012, 61:A298.
15. Rohloff C.M., Alessi T.R., Yang B., et al. DUROS technology delivers peptides and proteins at consistent rate continuously for 3 to 12 months. J Diabetes Sci Technol 2008, 2:461-467.
16. Yang B., Negulescu C., D'vaz R., et al. Stability of ITCA 650 for continuous subcutaneous delivery of exenatide at body temperature for 12 months. Presented at: the Ninth Annual Diabetes Technology Meeting; November 5-7 2009, San Francisco, Calif. Abstract No. A189.
17. Cefalu W.T., Parker T.B., Johnson C.R. Validity of serum fructosamine as index of short-term glycemic control in diabetic outpatients. Diabetes Care 1988, 11:662-664.
18. Lindsey C.C., Carter A.W., Mangum S., et al. A prospective, randomized, multicentered controlled trial to compare the annual glycemic and quality outcomes of patients with diabetes mellitus monitored with weekly fructosamine testing versus usual care. Diabetes Technol Ther 2004, 6:370-377.
19. Wallace T.M., Levy J.C., Matthews D.R. Use and abuse of HOMA modeling. Diabetes Care 2004, 27:1487-1495.
20. Fineman M., Flanagan S., Taylor K., et al. Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing. Clin Pharmacokinet 2011, 50:65-74.
21. Taylor K., Gurney K., Han J., et al. Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years. BMC Endocr Disord 2011, 11:9.
22. Cooke C.E., Lee H.Y., Tong Y.P., Haines S.T. Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization. Curr Med Res Opin 2010, 26:231-238.
23. Fabunmi R., Nielsen L.L., Quimbo R., et al. Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine. Curr Med Res Opin 2009, 25:777-786.